Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis

ClinicalTrials.gov ID

NCT07257887

Lead Sponsor

ENIKAM d.o.o.INDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

90Estimated

Last Update Posted

Dec 2, 2025Actual

Start Date

Nov 19, 2025Actual

Primary Completion Date

May 31, 2026Estimated

Completion Date

May 31, 2026Estimated

Official Title

Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis

Brief Summary

Periodontitis is a chronic, irreversible inflammatory disease affecting the supporting structures of the teeth. It is most commonly caused by bacteria in dental plaque, also known as biofilm. The disease typically begins as gingivitis, a reversible inflammation of the gums resulting from plaque accumulation. Without appropriate intervention-such as maintaining proper oral hygiene and removing plaque-gingivitis can progress to periodontitis, leading to the loss of clinical attachment, alveolar bone resorption, and eventually tooth loss.

Early diagnosis and regular treatment of periodontal disease are essential to prevent disease progression. The treatment of periodontitis is primarily causal and involves the mechanical removal of plaque. Initial therapy is non-surgical, consisting of scaling and root planing, and may be followed by surgical procedures if required. In addition to mechanical cleaning, increasing attention has been given to adjunctive, non-invasive therapies such as mouth rinses or oral solutions containing chlorhexidine or hydrogen peroxide. These agents have antimicrobial properties, help reduce plaque accumulation, and support tissue healing.

Hydrogen peroxide mouth rinses have been used for more than a century as an adjunct to mechanical plaque removal and for the prevention or management of oral infections. However, despite their long history of use, clinical studies evaluating hydrogen peroxide-based mouth rinses remain limited and heterogeneous in design, which makes it difficult to compare findings across studies.

The objective of this post-marketing clinical study is to generate additional data on the safety and efficacy of a hydrogen peroxide mouth rinse as an adjunctive therapy in the treatment of periodontitis. The study will evaluate two hydrogen peroxide concentrations: a 1.5% solution (Oroxid® sensitive) and a 3% solution (Oroxid® forte).

• Periodontal Disease

• OROXID® forte oral solution
• OROXID® sensitive oral solution
• Standard of Care

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Systemically healthy participants aged 18 years or older.
2. Generalized periodontitis, Stage III, Grade B.
3. Presence of three or more periodontal pockets deeper than 5 mm.
4. At least 16 natural teeth (excluding wisdom teeth).
5. Ability to comply with oral hygiene instructions following the intervention.
6. Signed informed consent form after being fully informed about the study.

Exclusion Criteria:

1. Periodontal treatment within the past six months.
2. Dental procedures (surgery, professional cleaning, scaling and root planing, laser therapy, piezotome) within the past six months.
3. Periodontitis, Stage IV.
4. Use of mouth rinses or oral gels within the past month.
5. Use of antibiotic therapy within the past three months.
6. Ongoing therapy with antihypertensives, antilipemics, antiarrhythmics, or other cardiovascular medications.
7. Systemic diseases such as diabetes, HIV/AIDS, liver diseases, chronic kidney disease, tuberculosis, and autoimmune disorders (e.g., lupus, scleroderma, Crohn's disease).
8. History of cardiovascular diseases, including acute myocardial infarction, angina pectoris, heart failure, atrial fibrillation, atrioventricular block, peripheral artery disease, or stroke.
9. Therapy with immunosuppressive agents.
10. Allergy to any ingredients of the study products.
11. Pregnant or breastfeeding women.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

ENIKAM d.o.o.INDUSTRY

info@ustna-medicina.com0038612323235

• Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Gingivitis

  NCT07270705

  RecruitingInterventionalNot ApplicableUpdated Dec 8, 2025
• Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Oral Cavity Surgery

  NCT06987253

  RecruitingInterventionalNot ApplicableUpdated Dec 1, 2025
• Clinical Study of a Formulation Containing Phtalox® in Periodontal Disease

  NCT05119283

  CompletedInterventionalNot ApplicableUpdated Dec 6, 2024
• In-office and Domiciliary Use of a New Ozonized Gel for the Management of Periodontal Disease

  NCT05254288

  CompletedInterventionalNot ApplicableUpdated Oct 20, 2022
• Effect of a Hydrogen-Peroxide and Hyaluronic-Acid Mouthwash (BMG0703) in the Treatment of Periodontitis

  NCT04446533

  Unknown statusInterventionalPhase 3Updated Jun 25, 2020
• Probiotics And Ozonated Olive Oil To Maintain Oral Eubiosis In Stage I And II Periodontitis Patients

  NCT06955546

  CompletedInterventionalNot ApplicableUpdated May 31, 2025